SC
BIOA

Stempoint Capital’s BioAge Labs BIOA Stock Holding History

Stempoint Capital’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.92M Buy
+338,654
New +$6.52M 1.13% 30

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Stempoint Capital's BIOA Position: Q1 2026 in Review

Stempoint Capital opened a new position in BioAge Labs (BIOA) in Q1 2026: 338,654 shares worth $5.92M. The stake represents 1.13% of the portfolio and ranks #30 among its holdings.

144 funds tracked by Wall St. Rank hold BIOA as of Q1 2026.

  • Stempoint Capital held 338,654 shares of BioAge Labs worth $5.92M as of Q1 2026.
  • BioAge Labs was a new Stempoint Capital position in Q1 2026.
  • BioAge Labs made up 1.13% of Stempoint Capital's portfolio in Q1 2026, its #30 holding.
  • 144 funds tracked by Wall St. Rank held BioAge Labs as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.